

**Anti-DLL3 Reference Antibody (rovalpituzumab)  
Recombinant Antibody  
Catalog # APR10108****Specification**

---

**Anti-DLL3 Reference Antibody (rovalpituzumab) - Product Information**


Application	FC, E, FTA
Primary Accession	<a href="#">Q9NYJ7</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.02 KDa

**Anti-DLL3 Reference Antibody (rovalpituzumab) - Additional Information****Target/Specificity**  
DLL3**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-DLL3 Reference Antibody (rovalpituzumab) - Protein Information****Name** DLL3**Function**  
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).**Cellular Location**  
Membrane; Single-pass type I membrane protein**Anti-DLL3 Reference Antibody (rovalpituzumab) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


## Anti-DLL3 Reference Antibody (rovalpituzumab) - Images




Anti-DLL3 Reference Antibody (rovalpituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-DLL3 Reference Antibody (rovalpituzumab) is more than 98.44%, determined by SEC-HPLC.



Immobilized human DLL3 His at 2  $\mu\text{g/mL}$  can bind Anti-DLL3 Reference Antibody (rovalpituzumab)  $\square$   $\text{EC}_{50} = 0.01407 \mu\text{g/mL}$



Human DLL3 HEK293 cells were stained with Anti-DLL3 Reference Antibody (rovalpituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC161=0.01586 µg/mL